TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2406298
Drug: Nicardipine 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 90 mg/day
Study: 7631894
Drug: Propranolol 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 240 mg/day
Study: 30053856
Drug: Higher vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher vegetable intake (mean 324.6 ± 196.1 g/day)
Study: 24509968
Drug: Adapalene-benzoyl peroxide
Normalized name: Adapalene-Benzoyl Peroxide Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene-benzoyl peroxide topical gel
Study: 23890405
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine
Study: 22882692
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (healthy controls)
Study: 22882692
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (GMT)
Study: 22882692
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (GMT)
Study: 22882692
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (healthy controls, GMT)
Study: 18180628
Drug: Hydrocodone/acetaminophen (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen (25 mg/2500 mg/d)
Study: 18180628
Drug: Tramadol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (200 mg/d)
Study: 12972172
Drug: LSG 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSG 1200 mg/day
Study: 12972172
Drug: LSG 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSG 1500 mg/day
Study: 3945915
Drug: Thermoradiotherapy (heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermoradiotherapy (heating tumor to 42-43.5 degrees C using electromagnetic waves at 915 MHz, total ionizing radiation dose of 40 Gy)
Study: 3945915
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (radiation therapy only)
Study: 9766765
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg t.i.d.) plus paroxetine (20 mg/day)
Study: 8142123
Drug: Intraarterial chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy
Study: 8142123
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone or radiotherapy combined with surgery and/or chemotherapy
Study: 26253800
Drug: Buffered 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered 4% lidocaine with 1:100,000 epinephrine buffered with 0.18 mL 8.4% sodium bicarbonate
Study: 11791098
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza virus vaccine (CAIV-T) administered by intranasal spray
Study: 11791098
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza virus vaccine (CAIV-T)
Study: 8736266
Drug: GHRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1 microgram/kg i.v.) combined with arginine (0.5 g/kg i.v.)
Study: 361333
Drug: Oral oxprenolol
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxprenolol 80 mg
Study: 26825017
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline at a dose of 1.5mlkg ‐1 h ‐1 for 12h before surgery
Study: 18162832
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus (LGG) therapy for 4 weeks
Study: 12681877
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of doxycycline orally twice a day for 7 days
Study: 12681877
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of doxycycline orally twice a day for 3 days followed by an oral placebo twice daily for the last 4 days
Study: 10389286
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg) every day for six months
Study: 10389286
Drug: Premarin (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin (0.625 mg) every day plus Provera (5 mg) from day 1 to day 12 every month for six months
Study: 8684694
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 gel (0.5 mg) for cervical ripening and intravaginal PGE2 gel (2 mg) for induction of labor
Study: 1880796
Drug: Tryptophan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (50 mg/kg/day)
Study: 22646140
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of intravenous proton pump inhibitors (PPIs)
Study: 22646140
Drug: High-dose intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intensive intravenous regimen of PPIs
Study: 22646140
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of intravenous PPIs
Study: 20219293
Drug: Chestnut's Bloomington
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chestnut's Bloomington Outpatient Treatment (CBOP) without ACC
Study: 20219293
Drug: Chestnut's Bloomington
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chestnut's Bloomington Outpatient Treatment (CBOP) with ACC
Study: 20219293
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) without ACC
Study: 20219293
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) with ACC
Study: 15901745
Drug: Progesterone (PG)
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone (PG) intravenous infusion
Study: 9793768
Drug: Intraoperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative mitomycin C (0.02% solution, applied for 3 minutes)
Study: 7867870
Drug: Orlistat 80
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 80 mg, three times daily for 8 days
Study: 356249
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren) 25 mg t.i.d. for 14 days
Study: 356249
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg b.i.d. for 14 days
Study: 9257670
Drug: Iloprost (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (8 hours/day i.v. infusion)
Study: 9257670
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet medication (Control)
Study: 3620398
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin protocol
Study: 3620398
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin protocol
Study: 20523971
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g glucose administration
Study: 20523971
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose administration
Study: 10773778
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) - 8 1-hour sessions of individual cognitive therapy for 6 weeks, followed by 6 2-hour sessions of social skills training (SST) in group weekly
Study: 10773778
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) - after switching group 2 to CBT
Study: 10773778
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (ST) - 12 weeks (6 half-hour sessions)
Study: 8873158
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose neuraxis irradiation (3,600 cGy/20 fractions)
Study: 1736336
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine at bedtime for 2 weeks
Study: 6093656
Drug: Aminophylline (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (9 mg/kg)
Study: 20886791
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with acupoint sticking therapy (observation group)
Study: 9661554
Drug: i.v. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketorolac 5 mg
Study: 9661554
Drug: i.v. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketorolac 12.5 mg
Study: 9661554
Drug: i.v. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketorolac 15 mg
Study: 9661554
Drug: i.v. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketorolac 30 mg
Study: 24401291
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of bioactive collagen peptide (BCP) VERISOL® once daily for 8 weeks
Study: 24401291
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of bioactive collagen peptide (BCP) VERISOL® after 8 weeks
Study: 18227295
Drug: Patient-specific heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific heparin concentration-based protocol
Study: 18227295
Drug: Standard weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight-based heparin dose (400 U/kg)
Study: 1962778
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy for stage II and IIIA nonsquamous cancer
Study: 1962778
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for stage I disease
Study: 1962778
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy for stage II and IIIA squamous cell carcinoma
Study: 6448429
Drug: naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500 mg initially, followed by 250 mg as needed, max 1250 mg daily)
Study: 16111600
Drug: Intraoperative fluoroscopic
Normalized name: Fluoroacetic acid F-18
DrugBank: Fluoroacetic acid F-18 (DB15202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative fluoroscopic dose assessment (I-FL)
Study: 16111600
Drug: Intraoperative fluoroscopic
Normalized name: Fluoroacetic acid F-18
DrugBank: Fluoroacetic acid F-18 (DB15202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative fluoroscopic dose assessment (I-FL) for Pd-103
Study: 11825631
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin administration (SC)
Study: 7128186
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide (200 mg)
Study: 16998094
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (300 mg/d)
Study: 26944539
Drug: Extended progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended progesterone treatment combined with eCG
Study: 23768612
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein (WP) 30 g
Study: 23768612
Drug: Casein Protein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein Protein (CP) 30 g
Study: 23768612
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) 33 g
Study: 22439807
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone undecanoate (TU) four times/year for 36 months
Study: 8920704
Drug: Schwarz standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz standard measles vaccine (SW-STD,10m)
Study: 8920704
Drug: Schwarz high-titre
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz high-titre vaccine (SW-HT,5m)
Study: 21992490
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) injection 0.015%
Study: 17604592
Drug: Opioid monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid monotherapy (group OO)
Study: 15555792
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group resuscitated according to the Baxter formula (4 ml/kg BW/% BSA burn)
Study: 11173893
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG supplementation with standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.) for 14 days
Study: 11173893
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.)
Study: 9493716
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration (exact dosage and duration not specified)
Study: 3501162
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (AP)
Study: 30801621
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (AC)
Study: 17535146
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus an individually tailored exercise program administered twice daily from hospital admission to discharge
Study: 8072075
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 20 micrograms prostaglandin E1 with 10 mg procaine
Study: 8072075
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 20 micrograms prostaglandin E1 with 20 mg procaine
Study: 7817169
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose heparin
Study: 25256813
Drug: One-third dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-third dose bacillus Calmette‐Guérin maintenance therapy every 6 months (3 weekly instillations)
Study: 25256813
Drug: One-third dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-third dose bacillus Calmette‐Guérin maintenance therapy every 3 months (2 weekly instillations)
Study: 25256813
Drug: One-third dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-third dose bacillus Calmette‐Guérin maintenance therapy
Study: 23253774
Drug: Peri-interventional antibiotic
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-interventional antibiotic prophylaxis (1.2 g amoxicillin/clavulanic acid during stent insertion)
Study: 23253774
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose antibiotic treatment (625 mg amoxicillin/clavulanic acid once daily until stent removal)
Study: 16732095
Drug: Buprenorphine 0.05-0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.05-0.6 mg/70 kg
Study: 15307696
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus 15 ml of milkvetch injection (MI) every 12 hrs for 14 days
Study: 10835440
Drug: 1 mg/h
Normalized name: fentanyl 0.1 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/h nimodipine (low-dose)
Study: 25185672
Drug: Alogliptin mono-therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin mono-therapy
Study: 22268920
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily for 60 days
Study: 18492839
Drug: Prebiotic-supplemented hypoallergenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic-supplemented hypoallergenic formula (8 g/L scGOS/lcFOS)
Study: 18492839
Drug: Placebo-supplemented hypoallergenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-supplemented hypoallergenic formula (8 g/L maltodextrin)
Study: 15876285
Drug: Twice-daily regimens
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily regimens based on stavudine immediate release or zidovudine
Study: 7634805
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg i.v. over 30 mins)
Study: 30919151
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (500 mg levofloxacin without enema)
Study: 30919151
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (500 mg levofloxacin plus enema)
Study: 29282143
Drug: Azithromycin (12-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (12-month course, weekly)
Study: 26703278
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.4% (Group A)
Study: 26703278
Drug: Topical bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bromfenac 0.09% (Group B)
Study: 26703278
Drug: Topical nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nepafenac 0.1% (Group C)
Study: 23909049
Drug: Atopy patch
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopy patch tests with aeroallergens (1 x skin prick tests concentration)
Study: 8491069
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg acetaminophen
Study: 2663318
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ibuprofen
Study: 8388307
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1500 mg/day)
Study: 3802699
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal plus 75 ml 70% sorbitol
Study: 22702906
Drug: Elacytarabine 2000
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elacytarabine 2000 mg/m² per day continuously i.v. during days 1‐5 every 3 weeks
Study: 11220425
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam administered 30 min preoperatively
Study: 11220425
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam administered at induction of anesthesia
Study: 8032065
Drug: Sustanon 250
Normalized name: SUSTAGEN PWDR CHOCOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustanon 250 (250 mg, 1 ml)
Study: 29751823
Drug: KENKOJISEICHI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: KENKOJISEICHI group - 90-minute sessions twice per week for 6 months
Study: 31597690
Drug: Vaccine hesitancy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine hesitancy screening (15-item PACV survey)
Study: 27530285
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg droperidol
Study: 27530285
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg + 10 mg droperidol (repeated at 15 min)
Study: 14671681
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of 500 mg ASA and 30 mg PSE
Study: 14671681
Drug: Preliminary formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preliminary formulation of ASA and PSE
Study: 8993754
Drug: IMREGR-1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMREGR-1 treatment
Study: 6386019
Drug: Preservative-free morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free morphine 4 mg in saline
Study: 30782586
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment of COPD exacerbation
Study: 30782586
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment for COPD exacerbation
Study: 23724696
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy on PC 6 (Neiguan) and additional acupuncture points (PC 4, HT 7, PC 7, PC 5, PC 3, CV 17, CV 6, BL 15, L 20, BL 17, BL 23, BL 18, HT 5, ST 36)
Study: 23724696
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug regimen (e.g., Nitroglycerine, Isosorbide mononitrate, Propranolol)
Study: 6698348
Drug: Cimetidine administration
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine administration
Study: 27215502
Drug: Indacaterol (IND)
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol (IND) 75 μg once daily (q.d.)
Study: 22752776
Drug: Subcutaneous BT088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous BT088 (200 IU, 0.4 mL)
Study: 8919896
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection during the application of 20 cm H2O positive airway pressure for 5 s (Manoeuvre I)